Greater Los Angeles Clinical Center of the Consortium for the Study of Chronic Pancreatitis, Diabetes and Pancreatic Cancer

慢性胰腺炎、糖尿病和胰腺癌研究联盟大洛杉矶临床中心

• 批准号: 10447160
• 负责人: Mark Goodarzi
• 金额: $ 50.71万
• 依托单位: CEDARS-SINAI MEDICAL CENTER
• 依托单位国家: 美国
• 财政年份: 2015
• 资助国家: 美国
• 起止时间: 2015-09-28 至 2025-06-30
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10447160
• 关键词: Adult; Ancillary Study; Area; Artificial Intelligence; Biological Assay; California; Cancer Detection; Child; Childhood; Chronic Phase; Clinical; Clinical Management; Clinical Research; Clinical Treatment; Clinical Trials; Clinical Trials Data Monitoring Committees; Cohort Studies; Collaborations; Complex; County; Development; Diabetes Mellitus; Diagnosis; Diagnostic; Early Diagnosis; Enzymes; Exocrine pancreas; Exocrine pancreatic insufficiency; Functional disorder; Future; Genetic Predisposition to Disease; Goals; Health system; Healthcare Systems; Human; Institutes; Leadership; Los Angeles; Malignant neoplasm of pancreas; Medical center; Methods; Modeling; Morbidity - disease rate; National Cancer Institute; National Institute of Diabetes and Digestive and Kidney Diseases; Natural History; Non-Insulin-Dependent Diabetes Mellitus; Pancreatic Diseases; Pancreatic Ductal Adenocarcinoma; Pancreatic enzyme; Pancreatitis; Pathogenicity; Patients; Pharmacologic Substance; Principal Investigator; Public Health; Recurrence; Research; Research Personnel; Resources; Risk Factors; Role; Series; Site; Techniques; United States; United States National Institutes of Health; Universities; X-Ray Computed Tomography; acute pancreatitis; base; blood glucose regulation; chronic pancreatitis; clinical center; design; disorder risk; epidemiology study; ethnic diversity; imaging modality; liquid biopsy; novel; novel diagnostics; organizational structure; participant retention; predictive modeling; premalignant; recruit; response; study population; treatment trial; working group

This is an application for renewal of Clinical Center designation of the Consortium for the Study of Chronic Pancreatitis, Diabetes, and Pancreatic Cancer (CPDPC). The Greater Los Angeles Clinical Center has provided considerable leadership in the organization and progress of the CPDPC. Dr. Pandol serves as co-chair of the Steering Committee and Dr. Goodarzi co-chairs the Type 3c Working Group. We have excelled in recruitment and retention of participants in the cohort studies implemented through the CPDPC designed to elucidate the natural history and develop means of diagnosis, treatment and clinical management of chronic pancreatitis (CP) and its complications in children and adults, and to determine the pathogenic interrelationships of diabetes and pancreatic cancer and develop the means of early diagnosis and management of pancreatic cancer. In addition, we have been performing a number ancillary and associated studies to support the overall goals of CPDPC, including: 1. Epidemiologic studies defining risk factors for pancreatic cancer and the natural history of CP; 2. Determining that genetic susceptibility for type 2 diabetes is a strong risk factor for diabetes associated with CP; 3. Developing liquid biopsy assays for aiding in the diagnosis of pancreatic cancer and CP; 4. Investigating mechanisms of pancreatitis and pancreatic cancer for rational pharmaceutical treatments; and 5. Conducting pilot clinical trials for treatment of recurrent acute and chronic pancreatitis. For the next phase of the CPDPC we are committed to the following Specific Aims: 1. Continue recruitment and retention of subjects in CPDPC cohort studies (PROCEED, INSPPIRE 2, NOD, DETECT) in existing and additional study sites, as well as increase diversity in the study population. 2. Continue currently supported ancillary studies to further develop risk factor models combined with liquid biopsy assays for early diagnosis of chronic pancreatitis and pancreatic cancer, and advance mechanism- based treatments and clinical trials for recurrent acute and chronic pancreatitis and pancreatic cancer. 3. Build models that combine clinical features with genetic susceptibility to allow the prediction of future development of diabetes in patients with chronic pancreatitis. 4. Determine the role of pancreatic enzyme replacement in regulating glucose homeostasis in patients with chronic pancreatitis and diabetes, with or without pancreatic exocrine insufficiency. 5. Use existing and annotated pre-diagnostic CT scans to develop artificial intelligence-based techniques for highly sensitive and specific methods for CT-based early pancreatic cancer detection. Our Center involves Cedars-Sinai Medical Center, UCLA Medical Center, the VA Greater Los Angeles Healthcare System and the University of Southern California/Los Angeles Public Health System with an organizational structure designed to expand recruitment into cohort studies of CPDPC with increased diversity and to facilitate our participation in ancillary studies.

这是慢性病研究联盟临床中心指定更新的申请 胰腺炎、糖尿病和胰腺癌（CPDPC）。大洛杉矶临床中心提供 在 CPDPC 的组织和进展中发挥了相当大的领导作用。 Pandol 博士担任该委员会的联合主席 指导委员会和 Goodarzi 博士共同主持 3c 类工作组。我们在招聘方面表现出色 以及通过 CPDPC 实施的队列研究中参与者的保留，旨在阐明 慢性胰腺炎（CP）的自然史并开发诊断、治疗和临床管理的方法 及其儿童和成人的并发症，并确定糖尿病和糖尿病的致病相互关系 胰腺癌并开发胰腺癌的早期诊断和治疗手段。此外， 我们一直在进行大量辅助和相关研究来支持 CPDPC 的总体目标， 包括： 1. 定义胰腺癌危险因素和 CP 自然史的流行病学研究； 2. 确定 2 型糖尿病的遗传易感性是与 CP 相关的糖尿病的一个重要危险因素； 3. 开发液体活检检测方法以辅助诊断胰腺癌和 CP； 4. 调查 胰腺炎和胰腺癌的合理药物治疗机制； 5. 指挥 治疗复发性急性和慢性胰腺炎的试点临床试验。对于 CPDPC 的下一阶段，我们 致力于以下具体目标： 1. 继续在 CPDPC 队列研究中招募和保留受试者（PROCEED、INSPPIRE 2、NOD、 DETECT）在现有和其他研究地点，以及增加研究人群的多样性。 2. 继续目前支持的辅助研究，进一步开发与液体相结合的风险因素模型 慢性胰腺炎和胰腺癌早期诊断的活检检测以及先进机制- 基于复发性急慢性胰腺炎和胰腺癌的治疗和临床试验。 3. 建立将临床特征与遗传易感性相结合的模型，以预测未来 慢性胰腺炎患者发生糖尿病。 4.确定胰酶替代在调节糖尿病患者葡萄糖稳态中的作用 慢性胰腺炎和糖尿病，伴或不伴胰腺外分泌功能不全。 5. 使用现有的和带注释的诊断前 CT 扫描来开发基于人工智能的技术 基于 CT 的早期胰腺癌检测的高度灵敏和特异的方法。 我们的中心包括雪松西奈医疗中心、加州大学洛杉矶分校医疗中心、VA 大洛杉矶医疗中心 医疗保健系统和南加州大学/洛杉矶公共卫生系统 旨在扩大 CPDPC 队列研究招募范围并增加多样性的组织结构 并促进我们参与辅助研究。